ライフサイエンスコーパス: tumor specificity

1 data partially explain the observed in vivo tumor specificity.

2 ing agents and TRAIL molecules with improved tumor specificity.

3 or imaging with nanoprobes suffers from poor tumor specificity.

4 sting that another mechanism underlies NDV's tumor specificity.

5 ental, but not control, tumors, establishing tumor specificity.

6 read distribution of delivered cells without tumor specificity.

7 seems to be important for the maintenance of tumor specificity.

8 estricted by severe side effects and lack of tumor specificity.

9 ues to determine the tissue distribution and tumor specificity.

10 en challenging due to the lack of sufficient tumor specificity.

11 mal rearrangements have demonstrated greater tumor specificity.

12 M targeting moiety by characterizing its (1) tumor specificity, (2) expression level, (3) cellular in

13 rated in several in vivo cancer models, with tumor specificity achieved through display of an alpha(v

14 Because of its strong promoter activity, tumor specificity and capacity for clinical translation,

15 To both increase tumor specificity and decrease nonspecific side effects,

16 erapeutic target for melanoma because of its tumor specificity and expression in the majority of thes

17 naerobic growth conditions were required for tumor specificity and intratumoral replication.

18 s DNA-intercalating agent has relatively low tumor specificity and limited efficacy.

19 0 (NSC 748747), which displayed much broader tumor specificity and notably increased potency over the

20 r blood-brain barrier (BBB) penetration, low tumor specificity and rapid washout from tumors.

21 t display significantly enhanced potency and tumor specificity and suggests a divergent mechanistic r

22 we investigate the mechanistic basis for the tumor specificity and vast overexpression of FR-alpha.

23 ariants with lower in vivo toxicity and high tumor specificity, and therefore greater potential for c

24 tumors in BALB/c recipients and demonstrated tumor specificity, but had no therapeutic efficacy in th

25 verall, this well-tolerated therapy achieves tumor specificity by redirecting inflammation to a funct

26 Here, we demonstrate that Salmonella tumor specificity can be significantly improved via a su

27 ssing whether oncolytic viruses with reduced tumor-specificity can more effectively eliminate tumors

28 ent strategy should provide a high degree of tumor specificity for increasing the effectiveness of hy

29 vector (RRV), Toca 511, which has displayed tumor specificity in resected brain tumor material and b

30 a promising delivery vehicle because of its tumor specificity, increasing its intra-tumoral motility

31 rine MOSEC tumor cells indicate that Sindbis tumor specificity is not attributable to a species diffe

32 ique localization in tumors and its relative tumor specificity may make p32 a useful target in tumor

33 We document the anti-tumor specificity of a vector that systemically targets

34 ceptors have been developed that combine the tumor specificity of antibodies with T-cell effector fun

35 PD-1(-) cells was the limiting factor in the tumor specificity of cells derived from bulk CD8 TILs.

36 We showed that the tumor specificity of CYGB methylation in discriminating

37 ether, these results highlight the intrinsic tumor specificity of MILs and describe a novel approach

38 To improve the tumor specificity of our mesoporous silica nanoparticle

39 ined or separately, explain the differential tumor specificity of some MUC-1 antibodies and T cells.

40 Tumor specificity of the catalysts together with their a

41 Overall, tumor specificity of the CRAds was limited compared with

42 Furthermore, the tumor specificity of the immunity induced by the two cel

43 ntribution of multiple mechanisms to enhance tumor specificity of the microregions.

44 The tumor specificity of the MSN particle was improved with

45 1In/90Y-2IT-BAD-Lym-1 to the extent that the tumor specificity of the radioactive metabolites was los

46 e tumor-infiltrating lymphocytes (TILs), the tumor specificity of these TILs, and the correlation bet

47 We further showed the tumor specificity of this assay with multiple other epit

48 The tumor specificity of this response is thought to reflect

49 To enhance the tumor specificity of this vector, we have developed a co

50 ncer nanomedicines commonly suffer from poor tumor specificity, "off-target" toxicity, and limited cl

51 iple cancer types combined with an exquisite tumor specificity opens a new door to widespread applica

52 Lack of tumor specificity remains a major problem with chemother

53 ess cancer cell heterogeneity while endowing tumor specificity, the approach of charge shielding/desh

54 cers of many MuLVs are major determinants of tumor specificity, we tested the role of the SRS 19-6 Mu

55 ement in BiTE technology given its exquisite tumor specificity, which enables precise elimination of